Back to search

Poland· PL-100397313

Bortezomib Adamed

A bortezomib product containing bortezomibum, registered in Poland by Adamed Pharma S.A.. The same ATC class is registered in 3 of our 19 countries.

ATC L01XX32

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBortezomib AdamedATCL01XX32REGISTER NO.PL-100397313PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Bortezomib is registered in 3 of 19 countries.

Countries holding a registration under ATC L01XX32 (bortezomib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose

Bortezomib · ATC L01XX32

3 / 19 countries

  • Belgiumprice
  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Bortezomibum
Manufacturer
Adamed Pharma S.A.
Country
Poland (PL)
ATC code
L01XX32
ATC class
Bortezomib
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05900411003193

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

587 interactions on record for bortezomib.

Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bortezomib · interactions on record

587 records

  • 45 severe
  • 250 moderate
  • 66 minor
  • 226 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • RifampicinJ04AB02severe
  • RifabutinJ04AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bortezomib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bortezomib products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Abormib, Bortezomib Ever Pharma
  • Belgium · Bortezomib Eg, Bortezomib Eugia
  • Bulgaria · Bortezomib Ever Pharma, Бортезомиб Актавис
  • Cyprus · Bortezomib Pharmazac, Bortezomib Stada
  • Czechia · Bortezomib Ever Pharma, Bortezomib Msn
  • Germany · Bortezomib, Bortezomib Amarox
  • Denmark · Bortezomib Actavis, Bortezomib Ever Pharma
  • Spain · Bortezomib Aurovitas, Bortezomib Combix
  • Finland · Bortezomib Avansor, Bortezomib Ever Pharma
  • France · Bortezomib, Bortezomib Arrow
  • United Kingdom (Northern Ireland) · Bortezomib, Bortezomib Accord
  • Greece · Bortezomib Pharmazac, Bortezomib Sandoz
  • Croatia · Bortezomib Alpha-Medical, Bortezomib Ever Pharma
  • Hungary · Bortezomib Ever Pharma, Bortezomib Msn
  • Ireland · Bortezomib Aspire Pharma (Malta), Bortezomib Biotech Pharma Limited
  • Iceland · Bortezomib Accord, Bortezomib Actavis
  • Italy · Bortezomib Aurobindo, Bortezomib Dr. Reddy’s
  • Liechtenstein · Bortezomib Accord, Bortezomib Fresenius Kabi
  • Luxembourg · Bortezomib Eg
  • Latvia · Bortezomib Tzf
  • Malta · Bortezomib Clonmel, Bortezomib Dr. Reddy’s
  • Netherlands · Bortezomib Amarox, Bortezomib Cf
  • Norway · Bortezomib Accord, Bortezomib Ever Pharma
  • Portugal · Bortezomib Ever Pharma, Bortezomib Extrovis
  • Romania · Bortezomib, Bortezomib Dr. Reddy’s
  • Sweden · Bortezomib Avansor, Bortezomib Ever Pharma
  • Slovenia · Bortezomib Actavis, Bortezomib Ever Pharma
  • Slovakia · Bortezomib Ever Pharma, Bortezomib Glenmark

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/559dd66d-e563-4a86-a54f-a63e3fca84b6
GET /v1/drugs/559dd66d-e563-4a86-a54f-a63e3fca84b6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "2,5 mg",
  "packaging": "05900411003193 ¦ Rpz ¦ 132062\n1 fiol. 2,5 mg proszku",
  "substance": "Bortezomibum 2.5 mg",
  "common_name": "Bortezomibum",
  "pl_product_id": "100397313",
  "pozwolenie_nr": "25222",
  "auth_procedure": "DCP",
  "authorisation_validity": "2024-06-21"
}

See everything about bortezomib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.